Geographic variation in the susceptibilities of invasive isolates of Candida glabrata to seven systemically active antifungal agents: a global assessment from the ARTEMIS Antifungal Surveillance Program conducted in 2001 and 2002

M A Pfaller; S A Messer; L Boyken; S Tendolkar; R J Hollis; D J Diekema

doi:10.1128/JCM.42.7.3142-3146.2004

Back

Geographic variation in the susceptibilities of invasive isolates of Candida glabrata to seven systemically active antifungal agents: a global assessment from the ARTEMIS Antifungal Surveillance Program conducted in 2001 and 2002

Journal article

Open access

Peer reviewed

Geographic variation in the susceptibilities of invasive isolates of Candida glabrata to seven systemically active antifungal agents: a global assessment from the ARTEMIS Antifungal Surveillance Program conducted in 2001 and 2002

M A Pfaller, S A Messer, L Boyken, S Tendolkar, R J Hollis and D J Diekema

Journal of clinical microbiology, Vol.42(7), pp.3142-3146

07/2004

DOI: 10.1128/JCM.42.7.3142-3146.2004

PMCID: PMC446248

PMID: 15243073

Files and links (1)

url

https://doi.org/10.1128/JCM.42.7.3142-3146.2004View

Published (Version of record) Open Access

Abstract

We examined the susceptibilities to amphotericin B, flucytosine, fluconazole, posaconazole, ravuconazole, voriconazole, and caspofungin of 601 invasive isolates of Candida glabrata and grouped the isolates by geographic location: North America (331 isolates), Latin America (58 isolates), Europe (135 isolates), and Asia-Pacific (77 isolates). Caspofungin (MIC at which 90% of isolates tested are susceptible [MIC(90)], 0.12 microg/ml; 100% of strains are susceptible [S] at a MIC of </=1 microg/ml) and flucytosine (MIC(90), 0.12 microg/ml; 99.2% S) were the most active agents in all geographic regions. Fluconazole susceptibility was highest in the Asia-Pacific region (80.5% S, 3.9% resistant [R]) and lowest in North America (64% S, 10.3% R) and Latin America (62.1% S, 3.4% R). The extended-spectrum triazoles were most active in the Asia-Pacific region (90 to 96.1% S) and least active in North America (82.5 to 90.3% S). All 46 isolates that were resistant to fluconazole were susceptible to caspofungin (MIC(90), 0.06 microg/ml) and flucytosine (MIC(90), 0.12 microg/ml) and exhibited variable cross-resistance to posaconazole, ravuconazole, and voriconazole.

Antifungal Agents - pharmacology

Microbial Sensitivity Tests

Time Factors

Drug Resistance, Fungal

Candida glabrata - drug effects

Details

Title: Subtitle: Geographic variation in the susceptibilities of invasive isolates of Candida glabrata to seven systemically active antifungal agents: a global assessment from the ARTEMIS Antifungal Surveillance Program conducted in 2001 and 2002
Creators: M A Pfaller - Department of Pathology, Roy J and Lucille A Carver College of Medicine, University of Iowa, Iowa City, IA 52242, USA. michael-pfaller@uiowa.edu
S A Messer
L Boyken
S Tendolkar
R J Hollis
D J Diekema
Resource Type: Journal article
Publication Details: Journal of clinical microbiology, Vol.42(7), pp.3142-3146
DOI: 10.1128/JCM.42.7.3142-3146.2004
PMID: 15243073
PMCID: PMC446248
NLM abbreviation: J Clin Microbiol
ISSN: 0095-1137
eISSN: 1098-660X
Publisher: United States
Language: English
Date published: 07/2004
Academic Unit: Infectious Diseases; Epidemiology; Pathology; Internal Medicine
Record Identifier: 9983986263302771

Metrics

11 Record Views

144 Times Cited - Web of Science